Technique identifies chemotherapy-resistant cells within acute myeloid leukemia tumors

Although chemotherapy can sometimes cure acute myeloid leukemia and other hematologic cancers, many patients experience relapses when their tumors become resistant to available chemotherapies. This resistance may be caused by the survival and proliferation of chemotherapy-resistant cells that were already present in the tumor prior to treatment. Studying the characteristics of these cells could help researchers understand and develop better approaches to target chemotherapy-resistant cancers.

This month in the JCI, Anthony Letai and colleagues at the Dana-Farber Cancer Institute developed an assay to determine how variability within a population of can predict responses to chemotherapy in acute myeloid leukemia patients.

The assay, which was performed on , measured each cell's sensitivity to mitochondrial apoptosis, a type of cell death that is induced by many existing chemotherapies.

They determined that the least sensitive cells in a tumor could predict how successfully a patient responded to chemotherapy. Developing the ability to identify chemotherapy-resistant tumors and tumor cells prior to treatment may lead to clinical insights that improve therapeutic outcomes in and other cancers.


Explore further

Study provides new clues to leukemia resurgence after chemotherapy

More information: Patrick D. Bhola et al, Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia, Journal of Clinical Investigation (2016). DOI: 10.1172/JCI82908
Provided by JCI Journals
Citation: Technique identifies chemotherapy-resistant cells within acute myeloid leukemia tumors (2016, September 6) retrieved 19 August 2019 from https://medicalxpress.com/news/2016-09-technique-chemotherapy-resistant-cells-acute-myeloid.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more